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Rationale: Insulin (INS) resistance associated with hyperestrogenemias occurs in gesta-
tional diabetes mellitus, polycystic ovary syndrome, ovarian hyperstimulation syndrome,
estrogen therapies, metabolic syndrome, and obesity. The mechanism by which INS and
estrogen interact is unknown. We hypothesize that estrogen binds directly to INS and the
insulin receptor (IR) producing INS resistance.
Objectives: To determine the binding constants of steroid hormones to INS, the IR, and
INS-like peptides derived from the IR; and to investigate the effect of estrogens on the
binding of INS to its receptor.
Methods: Ultraviolet spectroscopy, capillary electrophoresis, and NMR demonstrated
estrogen binding to INS and its receptor. Horse-radish peroxidase-linked INS was used in
an ELISA-like procedure to measure the effect of estradiol on binding of INS to its receptor.
Measurements: Binding constants for estrogens to INS and the IR were determined
by concentration-dependent spectral shifts. The effect of estradiol on INS binding to its
receptor was determined by shifts in the INS binding curve.
Main Results: Estradiol bound to INS with a K d of 12×10−9 M and to the IR with a K d of
24×10−9 M, while other hormones had significantly less affinity. Twenty-two nanomolars
of estradiol shifted the binding curve of INS to its receptor 0.8 log units to the right.
Conclusion: Estradiol concentrations in hyperestrogenemic syndromes may interfere with
INS binding to its receptor producing significant INS resistance.
Keywords: polycystic ovarian syndrome, gestational diabetes mellitus, insulin resistance, sex hormone binding
globulin, ovarian hyperstimulation syndrome, obesity, metabolic syndrome, molecular complementarity
INTRODUCTION
Insulin (INS) resistance associated with hyperestrogenemias
occurs in gestational diabetes mellitus (GDM), polycystic ovary
syndrome (PCOS), ovarian hyperstimulation syndrome (OHSS),
estrogen therapies, metabolic syndrome, and obesity. The mech-
anism by which INS and estrogen interact is unknown, but both
in vitro and in vivo studies suggest that estradiol (E2) directly or
indirectly inhibits INS binding to, and/or activation of, the insulin
receptor (IR).
The concentration of estrogen hormones varies across a bio-
logically extraordinary range of almost three orders of magnitude
in the normal human being, ranging between 30 pg/ml (0.06 nM)
in normal males and menstruating females and 10 ng/ml (40 nM)
in some pregnant women (1–7). At plasma concentrations of E2
above about 1 nM, INS resistance often develops. Some degree of
Abbreviations: E2, estradiol; ERα, ERβ, alpha and beta chains of estrogen receptor;
ER, estrogen receptor; GDM, gestational diabetes mellitus; INS, insulin; INS–HRP,
insulin conjugated to horse-radish peroxidase; IR, insulin receptor; IVF, in vitro
fertilization; OHSS, ovarian hyperstimulation syndrome; PCOS, polycystic ovarian
syndrome; SHBG, sex hormone binding globulin.
INS resistance occurs in virtually all pregnant women and between
2 and 10% of pregnancies are so severely affected by GDM that
they require INS treatment (5–15). Similar rates of INS resistance
and diabetes occur as a result of OHSS in which E2 concentra-
tions often exceed 10 nM (16, 17). After parturition, INS sensitivity
typically returns rapidly to pre-pregnancy levels (1–10). High-
dose estrogen-containing contraceptives, but not low-dose ones,
have, in the past, also been associated with INS resistance and
hyperinsulinemia (18–24) and in men, elevated E2 (often result-
ing from aromatase conversion of testosterone to E2) is also an
independent risk factor for metabolic syndrome, as it may occur
during puberty or following synthetic androgen use in body build-
ing (3, 25–27). The development of INS resistance also occurs
in women who are treated with cyproterone acetate and ethinyl
estradiol for hirsutism and/or acne (28). Administration of E2 or
testosterone (which can be converted to E2) in persons undergo-
ing sexual reassignment is another cause of INS resistance (27,
29). And 45–70% of patients suffering from PCOS have vary-
ing severities of INS resistance associated with hyperinsulinemia
(30–39). In PCOS, concentrations of E2 can exceed 1 ng/ml or
4 nM (36, 37).
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All of these clinical observations suggest that INS resistance is
somehow related to the concentration of plasma E2.
In vitro experiments have helped to unravel some interactions
between E2 and INS. The effects of E2 on INS activity are tri-
modal. Cells that are grown in media lacking E2 or which are
exposed to hypoestrogenemic conditions develop significant INS
resistance as a result of decreased expression of IR and the glucose
transporter GLUT4 (40–46). Normal levels of E2 are associated
with normal INS and IR function. Cells exposed to hyperestro-
genemic conditions develop significant decrease in INS and IR
activity. Hypertestosterone syndromes such as PCOS may also
contribute indirectly to E2 inhibition of INS and IR since aro-
matase converts testosterone to E2 resulting in hyperestrogenemia
as well (30, 36, 47).
In vivo experiments and clinical studies confirm the in vitro
results. Ovariectomized (OVEX) rats respond to E2 levels 100
times those found in normal gestation by decreasing the number of
IR, increasing the serum concentration of INS threefold, decreas-
ing phosphorylation of IR substrate-1, and decreasing GLUT4
expression; INS resistance ensues (48–51). Two types of data sug-
gest that these rat studies can be extrapolated to human beings.
First, functionally ovariectomized people given E2 as part of sex
reassignment treatment also incur INS resistance in direct propor-
tion to the dose of E2 (27–29). Additionally, women undergoing
in vitro fertilization often reach supraphysiological levels of E2
>6,000 pg/ml (>10 nM) and develop INS resistance (52–59).
The combination of in vitro and in vivo and clinical studies
summarized above strongly suggests that E2 alone is sufficient to
induce INS resistance either directly or indirectly. Thus far, all
attempts to understand E2-related INS resistance have focused on
indirect mechanisms, such as reduced GLUT4 mRNA expression
and transport (11, 38), increased INS synthesis and secretion (40,
60), and interactions between IR, IR complex 1 estrogen-receptorα
(61). It is not clear whether these phenomena are, however, causes
or results of E2-mediated activity.
We propose that a more direct mechanism may contribute to
INS resistance in hyperestrogenemias: E2 may bind directly to INS
and/or the IR at pathophysiologically high concentrations of E2.
MATERIALS AND METHODS
SEX HORMONES
All hormones, selective estrogen-receptor modulators (SERMS)
were obtained from Sigma-Aldrich: 4-andro-stenedione (A9630),
cholesterol (C8667), corticosterone (C2505), estradiol (E1024),
estriol (E1253), estrone (E1274), hydrocortisone (H3160), 5-
Pregnen-3β-ol-20-one (P9129), progesterone (P3972), Raloxifene
HCl (R1402), Tamoxifen citrate salt (T9262), and Genistein
(92136). We did not test testosterone since our department lacks
the approval to obtain this controlled substance.
PEPTIDES
Human recombinant INS (I0259 or I2643), INS A chain, oxidized
(I1633) and INS B chain, and oxidized (I6383) and glucagon
(G3157) were obtained from Sigma-Aldrich. Humulin R was
obtained from Lilly. Peptides from the IR identified as being
INS- or glucagon-like peptides (Table 1) were synthesized by
the Mass Spectrometry, Synthesis, and Sequencing Facility of
Table 1 | Binding constants for various sex hormone binding to
recombinant human insulin (Humulin), the oxidized insulin A chain,
the oxidized insulin B chain, and glucagon.
Binding
constants
(M) at 225nm
Humulin
(human
insulin)
Insulin
alpha
chain
Insulin
beta
chain
Glucagon
17β-Estradiol (E2) 1.2E−8, 6.5E−5 2.2E−04 1.5E−04 >0.0005
17α-Estradiol 1.0 E−5 >0.0005 >0.0005 >0.0005
Estriol >0.0005 ND ND >0.0005
Estrone 1.25E−06 >0.0005 >0.0005 ND
Cholesterol >0.0005 >0.0005 ND ND
Progesterone >0.0005 ND ND ND
Hydrocortisone 6.35E−05 >0.0005 >0.0005 ND
Andro-stenedione 1.35E−05 >0.0005 >0.0005 ND
Corticosterone 2.11E−05 >0.0005 >0.0005 ND
Pregnenolone 5.70E−06 >0.0005 >0.0005 ND
Raloxifene 1.3E−04 ND ND ND
Tamoxifen >0.0005 ND ND ND
Genistein >0.0005 ND ND ND
Humulin has a high affinity binding site for 17-β-estradiol (E2) as well as a low
affinity site (see Figure 1). ND stands for “not done.”
the Biochemistry Department of Michigan State University and
purified to >98% purity as determined by high pressure liquid
chromatography.
RECEPTORS
Rat IR membrane preparation (I-9266) (IR) and human INS-
like growth factor receptor (IGFR) (I-4657) were obtained from
Sigma-Aldrich. The rat IR was a partially purified preparation in
residual membrane and contained 250 units of activity as mea-
sured by its ability to catalyze the incorporation of 1 pmol per min
of phosphate fromγ-32P-ATP into poly(Glu, Tyr), 4:1, at 30°C. The
IGFR was recombinant, at least 95% pure by SDS-PAGE, and capa-
ble of binding INS-like growth factor. Both receptor preparations,
in sum, retained activity.
UV SPECTROPHOTOMETRY
Ultraviolet spectroscopy was used to determine binding constants
of sex hormones to INS, INS peptides, IR peptides, IR, and IGFR.
This method has been used for decades by other investigators
(62–65) as well as by the authors of this paper (55, 56, 66–69).
Insulin receptor peptides were prepared at 100 nM in pH 7.4
phosphate buffer (Fisher Scientific). Humulin and human recom-
binant INS were prepared at 12.5 and 25 nM in pH 7.4 phos-
phate buffer. IR (250 units) and INS-like growth factor receptor
(50µg) were each prepared for assay by diluting the manufac-
turer’s receptor preparation in 1.0 ml pH 7.4 phosphate buffer to
about 3.5× 10−12 M.
Sex hormones and controls were dissolved in 95% ethyl alcohol
to 1.0 mM and diluted serially by thirds.
Hormone peptide binding studies were carried out as follows.
In two columns of the serially diluted steroid hormone, 100µL
of diluted peptide was added to the wells. One hundred micro-
liters of buffer was added to the other two columns containing
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FIGURE 1 | Curves showing concentration-dependent binding of various
sex hormones to recombinant human insulin (Humulin). Binding
constants (Table 1) were approximated by determining the inflection points of
these curves. Note that estradiol has two binding modes, a high affinity one
that is apparent at very low concentrations of E2 (Humulin 1/25 dilution) and a
lower affinity site that is present at higher concentrations of E2.
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FIGURE 2 | Serial additions of estradiol (E2) also demonstrated
concentration-dependent changes in the Humulin spectrum starting at
nanomolar concentrations of E2. E2 binding to cholesterol, in contrast,
was observable only at micromolar concentrations. These results confirm
the high affinity of E2 for insulin shown in Figure 1.
serially diluted steroid hormones. As controls, in a fifth column,
100µL of the diluted peptide was added to 100µL of 95% ethyl
alcohol in two wells. To two additional wells, 100µL of 95% ethyl
alcohol and 100µL of buffer were added. Plates were incubated at
room temperature for 30 min and were then read in a SpectraMax
384Plus from 200 to 290 nm. The differences between the expected
absorbance values (determined by adding the individual hormone
absorbances and the individual peptide, INS absorbances minus
the buffer–ethanol controls) and the observed value of the com-
binations were then plotted as a function of the concentration of
the hormone.
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FIGURE 3 | A serial addition experiment like that shown in Figure 2,
but starting with higher concentrations of Humulin and estradiols.
Even at 1000 times the concentration of E2 used in Figure 2, no binding
was apparent to the insulin A chain, nor did 17-α-estradiol, an E2 antagonist,
bind significantly to Humulin in this concentration range (Table 1).
An additional method of ascertaining binding involved serial
additions of estrogens to INS, INS peptides, or glucagon (as a con-
trol). Peptides were dissolved as above and 200µL added to a well
in a crystal 96-well plate. Two hundred microliters of buffer was
placed in an adjacent well in the plate. Five microliters of aliquots
of estrogens (1.0 or 0.1µM in 95% ethanol) or SERMS (100µM in
95% ethanol) were then added in tandem to the peptide well and
the buffer well. An additional buffer well received a 5µL aliquot
of ethanol each time an estrogen or SERM was added to any other
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FIGURE 4 | Curves showing concentration-dependent binding of various sex hormones to the oxidized B chain of insulin. Only estradiol (E2) showed
measurable binding (seeTable 1).
well. Additions were made serially. The UV spectrum was obtained
after each addition as above at 225 nm. In this way, all wells were
diluted with ethanol at the same rate and to the same concentra-
tions at each aliquot. The absorbance value of the buffer well after
each aliquot of ethanol was subtracted from each of the other wells
(peptides, hormones, or SERMS, and their combinations). The
absorbance value of the peptide, glucagon, or INS at each ethanol
concentration was determined; the absorbance value of each hor-
mone (or SERM) was determined; then these individual values
were added to provide an expected value of their combination in
accordance with Beer’s law. The difference between this expected
absorbance value after each aliquot addition and that obtained
from the actual experimental combination was then determined
and this difference was plotted as a function of the estrogen or
SERM concentration. All binding experiments were run in dupli-
cate and the results averaged. Binding constants were determined
from the inflection point of any S-shaped curves that resulted.
This serial addition method was also used to determine the
binding of estradiol to IR and IGFR.
CAPILLARY ELECTROPHORESIS
Capillary electropherograms of INS and estrogen were prepared at
a variety of voltages. Use of capillary electrophoresis to determine
binding between compounds was pioneered by this laboratory (70,
71). Human recombinant INS (0.6 mg/ml; Sigma-Aldrich) and
beta estradiol (1.5 mg/ml), and a combination of INS plus beta
estradiol at the same concentrations, were prepared in 50 mM pH
7.4 phosphate buffer and allowed to incubate at room tempera-
ture for 48 h. The estrogen was in crystalline form and did not
dissolve; only the supernatant, avoiding any estrogen crystals, was
used in the experiments. Each sample was then diluted in distilled
water 1:4 for a buffer concentration of 10 mM. Samples were vac-
uum injected into an Isco 3950 electropherograph 100µm inner
diameter glass capillary of 49 cm with a distance from injection
site to detection window of 27 cm. The carrier buffer was 10 mM
sodium phosphate. Samples were driven from injection site to
ground using positive voltage. Each sample containing INS alone,
estrogen alone, or both, was driven at 10, 15, 20, 25, and 30 kV.
Peaks were detected at 200 nm wavelength.
1H NUCLEAR MAGNETIC RESONANCE
Human recombinant INS (0.6 mg/ml; Sigma-Aldrich) and beta
estradiol (1.5 mg/ml), and a combination of INS plus beta estra-
diol at the same concentrations, were prepared in 99.98% D2O
(Sigma-Aldrich) and allowed to incubate at room temperature for
48 h. The solutions were at pH 5.5. Neither the E2 nor the INS
dissolved completely, so particulates were spun down for a minute
in a tabletop centrifuge and only the clear supernatant was used
in the experiments. Data were collected on an Agilent Technolo-
gies 500 MHz NMR machine in the Max T. Rogers NMR Facility
located in the Chemistry Department of Michigan State University.
A PROTON pulse sequence (s2pul) was used at 26.0°C. The relax-
ation delay was 1.000 s; Pulse 45.0°; acquisition time 2.045 s; width
8012.8 Hz; 2352 repetitions. The resulting data were processed to
minimize noise and to flatten the baseline.
ENZYME-LINKED INS BINDING ASSAY
In order to determine whether estradiol interfered with INS bind-
ing to the IR, a modified form of ELISA was used, employing INS
conjugated to horse-radish peroxidase (Sigma-Aldrich) in place
of an antibody (55, 56). IR was isolated from rat liver (Sigma-
Aldrich). A few crystals of estradiol were added to 1.0 ml solutions
of INS–HRP and IR solutions (concentrations below) and allowed
to bind for 48 h. Only the supernatant of these solutions was uti-
lized for further experimentation (i.e., only the solubilized fraction
of E2). For the ELISA, the IR and IGFR (with and without E2) was
utilized at 3.5× 10−12 M and the INS–HRP (with and without
E2) was serially diluted by thirds from an initial concentration of
50µM. The initial concentration of E2 solubilized by the INS–
HRP, INSR, and IGFR was, in each case, approximately 200 nM
(see below). 100µL of the IR or IGFR (with and without E2) was
plated first and allowed to bind to the Costar EIA/RIA 96-well plate
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FIGURE 5 | (A) Capillary electropherograms showing the relative
absorbance at 225 nm of insulin (INS) at the bottom, estradiol (E2) in the
middle, and their combination at the top, in 25 mM pH 7.4 phosphate buffer
at 30 and 15 kV. Since the area of a CE peak is proportional to the
concentration of the compound present, it is possible to calculate the ratio
of the INS and of the E2 present in the combinations as a function of the
individual samples as in (B). Note that some peaks are shared in both the
E2 and INS electropherograms and represent buffer material. (B) Illustrates
the fact that while the presence of E2 has no effect on the amount of INS
present in solution, the presence of INS increases the amount of E2 that is
solubilized by a factor of about 4. The mean±SD of the five EI/E ratios is
3.96± 0.45.
for 1 h with shaking at room temperature. The plate was then triply
washed with a 1% Tween 40 solution. 200µL of 1% polyvinyl alco-
hol (PVA) was added to each well and served as blocking agent.
An additional set of wells were incubated with buffer alone and
then the PVA to act as a control for non-specific binding in sub-
sequent steps. The PVA was incubated and washed as described
above. Next, 100µL of the INS–HRP (with and without E2) dilu-
tions was added to each well, incubated, and washed as above.
Finally, 100µL of 2,2′AZINO-bis (3-ethylbenziazoline-6-sulfonic
acid) (ABTS single reagent, Chemicon International) was added to
all wells, allowed to incubate for 30 min at room temperature, and
the absorbance of each well read at 405 nm. All combinations were
run in duplicate and the results averaged. Note that, because the
E2 was solubilized in INS–HRP, it, too, was serially diluted as the
INS–HRP was serially diluted. The concentration of E2 at the mid-
point in the resulting binding curves was therefore approximately
22 nM. It is also important to note that the estradiol concentration
was not directly controlled in this experiment and had to be deter-
mined by capillary electrophoretic (CE) (below). We found that
use of defined solutions containing ethanol above 30% destroyed
the assay.
To determine the concentration of E2 used in the experiment, a
few crystals of estradiol were added to 1.0 ml of buffer containing
either IR or INS–HRP and allowing these solutions to incubate
at room temperature for at least 48 h. The concentration estra-
diol was determined using CE (pH 8.4 borate running buffer)
and comparing the results to a series of known concentrations of
E2 prepared in 95% ethanol. The concentration of E2 in the E2-
saturated phosphate buffer in the presence of either INS or IR was
found to be approximately 200 nM (ca. 60 ng/ml) or about five
times the plasma concentration of E2 observed in third-trimester
pregnancy.
DATA ANALYSIS
All data from the UV spectroscopy and ELISA experiments were
analyzed and plotted using the Microsoft Office Excel spreadsheet
program. There are no statistics or error bars because all of the
methods used for determining curves and binding constants are
differences in absorbance that involved multiple subtractions.
RESULTS
Figure 1 and Table 1 summarize the UV spectroscopy results
of recombinant human INS binding to estradiol (E2), estriol,
estrone, hydrocortisone, andro-stenedione, corticosterone, and
pregnenolone and the SERM raloxifene. Estriol had a binding con-
stant >500µM, raloxifene 130µM, while the other five hormones
all had binding constants between 1.25 and 63.5µM. The only
hormone or SERM that bound within a physiological range was
E2, which had a binding constant of 12 nM. Figure 2 confirms
that measurable binding of E2 to INS is readily apparent at 10 nM,
but alpha estradiol, a very weak E2 agonist, does not bind signif-
icantly to INS even at 1µM. Binding of E2 to INS requires the
cooperation of both the A and B chains of INS, since the binding
constants for E2 binding to the individual oxidized chains is only
220 and 150µM, respectively (Table 1; Figures 3 and 4). The bind-
ing of E2 to INS-like peptides derived from IR provides additional
information about the specificity of the binding site. E2 does not
bind with measurable affinity to glucagon (Table 1).
Notably, the binding of E2 to INS is biphasic, displaying
high affinity binding (12 nM) and low affinity binding (65µM)
(Table 1; Figures 1 and 2). This biphasic binding suggests that
there are at least two binding sites for E2 on INS, but the lower
affinity site is unlikely to have any physiological or pharmacolog-
ical importance since INS and E2 never approach concentrations
even in the most extraordinary circumstances that would result in
measurable binding to this site.
Binding of E2 to INS was confirmed by CE and 1H nuclear
magnetic resonance spectroscopic (NMR) experiments. It is also
important to know that the area under a peak representing a chem-
ical species is, in CE, directly proportional to the concentration of
the chemical species over a wide range of concentrations. Figure 5
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Table 2 | Binding constants for various sex hormones and insulin to peptides derived from the human insulin receptor (IR).
Binding constants (M) at 225nm
peptide sequence
Insulin-
HRP
Estradiol Estriol Estrone Progesterone Andro-
stenedione
Prenen-
olone
Cholesterol
IR α 91–103 FRVYGLESLKDLF 7.0E−08 1.2E−04 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 105–118 LTVIRGSRLFFNY 1.8E−09 2.8E−04 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 223–234 CKSHGCTAEGLCC >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 233–248 CCHSECLGNCSQPDD 8.0E−09 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 284–300 SFCQDLHHKCKNSRRQG 8.5E−09 9.0E−07 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 392–404 SGYLKIRRSYALV 3.0E−07 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 424–441 NYSFYALDNQNLRQLWDW >0.0005 >0.0005 3.8E−04 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR α 453–464 TQGKLFFHYNPK 7.6E−09 >0.0005 3.9E−04 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
IR β 897–916 HLCVSRKHFALERGCRLRGL 1.5E−09 7.8E−07 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005 >0.0005
Several of these peptides have previously been associated with insulin binding sites in the IR (54–56) and two of these – both insulin mimics – have significant affinity
for estradiol (E2) as well. This finding is in accordance with insulin binding E2 (Table 1). Bolded figures are those that have physiological relevance.
shows the results for 15 and 30 kV experiments. Significantly, more
E2 was present in solution when the E2 was mixed with INS than
without. Table 2 shows that at each voltage, the peak ratio of estro-
gen from the estrogen/INS sample compared with the estrogen
alone sample was approximately 4:1, indicating that the presence
of INS causes a substantial increase in the amount of estrogen in
solution. This is possible only if INS binds E2 and is consistent
with the other experiments in this paper.
The results of the NMR experiments, illustrated in
Figures 6A,B, also indicate that E2 binds to INS. Significant
changes in the spectrum occur in both the aromatic region of
the spectrum, especially around 9.7 and 7.5 ppm, and also in the
region of the spectrum around 2 ppm. Most strikingly, a number
of peaks in both regions become so broadened or suppressed as to
disappear. All such peaks are associated in both INS and E2 with
aromatic hydrogens strongly suggesting that binding of E2 to INS
is mediated through interactions with the histidine, phenylalanine,
and/or tyrosine residues of the peptide, probably involving charge
transfer complexing.
UV spectroscopy revealed that E2 binds to the rat IR mem-
brane preparations with an affinity very similar to that of E2 for
INS. The binding of E2 to IR was biphasic with a high affinity bind-
ing having a K d of about 2.4× 10−8 and a lower affinity binding
with a K d above 10
−6 (Figure 7, top). E2 also bound to human
recombinant IGFR, again in a biphasic manner, with high affinity
binding of about 1.0× 10−7 and a lower affinity binding with a
K d above 10
−5 (Figure 7, bottom). The biphasic binding of E2 to
IR and IGFR, like that of E2 to INS itself, suggests the presence of
at least two binding sites for E2 on these receptors. As with INS,
the low affinity E2-binding sites are extremely unlikely to play any
physiological or pharmacological role.
Since we have demonstrated previously that IR and IGFR con-
tain significant regions of homology with INS itself (53–56), the
similarity between the binding constants for E2 to both INS, IR
and IGFR suggested that the INS-like regions of the IR and IGFR
might be the binding sites for E2. We again used UV spectrometry
to investigate whether steroid hormones bind directly to INS-like
peptides derived from the IR (characterization of IGFR will be
reported in the future). All of the IR peptides used in these exper-
iments are from extracellular regions of the IR, and all but one
(IR peptide 897–916) are found in the alpha chain of the IR (see
Table 2 for sequences and binding results). Some of the peptides
tested have previously been shown to bind INS in the nanomo-
lar range (55, 56) and are therefore likely to be involved in INS
binding to the IR (see Table 2 for INS binding data). E2 bound
to several of the IR peptides associated with INS binding, but at
about 15- to 20-fold higher concentrations of E2 than was found
for the intact rat IR preparations. E2 bound to IR peptides 284–300
(IR alpha chain) and 897–916 (IR beta chain) at 900 and 780 nM,
respectively (Table 2).
We next hypothesized that E2 binding to INS and to the IR
might alter the affinity of INS for the IR. In order to explore
this possibility, we used a simple enzyme-linked adsorption assay
employed in previous studies of INS binding to the IR (55, 56).
Figure 8 shows that the presence of E2 decreased binding of INS–
HRP to the IR by about half a log unit (fivefold) when incubated
with either INS or with the IR. When E2 was incubated with
both INS and the IR, an eightfold decrease in INS binding to
the IR resulted (Figure 6). It is important to emphasize that in
each of these cases, the concentration of E2 present was initially
at the maximum that INS or IR could bind in aqueous solution
(200 nM E2 as determined by capillary electrophoresis) but that
because the E2 was diluted in tandem with the INS and/or IR,
at the inflection points of the binding curves, the concentration
of E2 was about 22 nM and therefore likely represents the maxi-
mum possible effects that E2 could have under naturally occurring
hyperestrogenemic conditions.
DISCUSSION
Figures 1–6 and Tables 1 and 2 demonstrate, using UV spec-
troscopy, capillary electrophoresis, and NMR, that E2 binds to
INS. The UV spectroscopic studies (Figures 1–4; Tables 1 and 2)
show clear E2-concentration-dependent shifts in absorbance in
the nanomolar range, whereas most other estrogens, estrogen
precursors, and SERMS such as raloxifene, tamoxifen, and the phy-
toestrogen genistein have negligible binding to INS. These data are
consistent with the interpretation that E2 can cause INS resistance
by direct binding to INS and IR and that the other compounds,
including SERM studied here cannot produce such effects through
this mechanism. In fact, SERMS are not associated clinically with
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FIGURE 6 | 1H NMR spectra in D2O of insulin (INS) are shown at the
bottom, estradiol (E2) in the middle, and their combination (INS+E2) at
the top. (A) Spectral region from 0 to 3 ppm. While the various peaks of INS
and E2 ranges between 0.2 and 1.5 ppm and 2.5 and 3.0 ppm add to create
the INS–E2 spectrum (top), significant changes are also evident. The INS peak
at 1.8 ppm (dot) broadens out in the INS–E2 combination, while the INS and
E2 peaks at 2.3 ppm (dots) shift to 2.2 ppm. (B) Spectral region from 7 to
10 ppm. Again, some of the INS and E2 peaks are clearly additive to give the
INS+E2 spectrum on top, e.g., those at 7.2 and 7.6 ppm. Other peaks in this
region show major changes. The INS and E2 peaks (dots) at 9.8 ppm
disappear in the combination while those at 7.35 and 7.65 ppm in both INS and
E2 (dots) are quenched or shift to positions at 7.2 and 7.6 ppm. These spectral
changes are consistent with E2 binding to INS involving mainly aromatic
residues on both molecules.
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FIGURE 7 | Binding curves showing concentration-dependent effects of
increasing estradiol (E2) on the UV spectrum of the insulin receptor (IR)
at the top, and on the insulin-like growth factor receptor (IGFR) at the
bottom. Both curves are bimodal, showing high affinity and low affinity
(probably non-specific) binding. These curves mimic those of E2 binding to
insulin (Figure 1).
development of diabetes or even INS resistance (57–59, 72–74)
and phytoestrogens generally improve INS function (75–78).
The CE experiments (Figure 5) provide evidence that E2 bind-
ing to INS results in increased solubility of E2 in aqueous solution,
as there is four times as much E2 in solution when INS is present
as when it is absent. INS may therefore act as an E2 transporter
at appropriate concentrations of the two compounds. E2-binding
requires intact INS, as the oxidized INS A and B chains have very
reduced affinity for E2. Comparing the INS sequence with those
of the IR peptides that also bind E2 suggests that a single relatively
conserved motif is necessary for E2 binding (Table 3). This motif
consists of an arginine or lysine residue followed by a glycine or
leucine and then a series of aromatics, usually a pair of pheny-
lalanines and a tyrosine. At one or two amino acids removed, a
hydrophilic residue such as lysine or asparagine often rounds out
the motif.
The NMR study (Figures 6A,B) shows major shifts and quench-
ing of specific peaks associated with aromatic residues such as tyro-
sine and phenylalanine suggesting that the mechanism of binding
involves pi–pi bonding or charge transfer complexing between E2
and INS. The participation of tyrosine and phenylalanine residues
in E2 binding is not only logical, given the polyaromatic struc-
ture of E2 itself, but also in light of the structure of the conserved
E2-binding motif derived in Table 3.
E2 binds to INS with a K d of about 12 nM, but other steroid
hormones bind to INS with significantly less affinity so that
only E2 is likely to have an impact on INS activity under
physiological conditions. The impact of E2 binding to INS is
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FIGURE 8 | Curves showing the effects of estradiol (E2) on the binding
of insulin conjugated to horse-radish peroxidase (INS–HRP) to isolated
insulin receptor (IR). The beginning concentration of E2 was 200 nM as
measured by capillary electrophoresis (data not shown), which was diluted
in tandem with the INS–HRP. The mid-point concentration of E2 in each
curve was therefore about 22 nM. E2 shifted the binding curve to the right
about half a log unit (a fivefold decrease in binding) when incubated with
either INS–HRP or the IR alone, and it shifted the binding curve to the right
0.8 log units (an eightfold decrease in binding) when both the IR and
INS–HRP were exposed to E2.
evaluated in Table 4. Assuming standard binding constant kinetics
[K d= (INS)(E2)/(INS–E2 complex)], it follows that at 12 nM E2,
half of the INS will be complexed with E2. Concentrations of E2
exceeding 12 nM E2 are observed in a number of syndromes asso-
ciated with INS resistance including third-trimester pregnancy,
GDM, and OHSS, so that in these syndromes, more than half of the
available INS will likely be bound to E2 at any given time, decreas-
ing INS binding to its receptor (Figure 8). Given that over half the
INS in the body would have impaired function at any given time,
it would be natural for the body to “over-produce” INS to com-
pensate. Table 3 shows that increasing the concentration of INS
threefold results in about a 2.5-fold increase in free INS. At concen-
trations of E2 that are typical of normal males and non-pregnant
females (ca. 6× 10−11 M), on the other hand, complexing of E2
to INS will be negligible [on the order of two-tenths of a percent,
ignoring binding of E2 to sex hormone binding globulin (SHBG),
which will decrease the amount of free E2 and therefore of E2–INS
as well]. Thus, the huge variation in E2 concentrations observed in
human beings results in very large and very significant differences
in the amounts E2 bound to INS.
As Table 3 illustrates, the impact of E2 and INS concentra-
tion variations occur between the normal baseline ranges and the
extremes of pregnancy and over-production syndromes. Quadru-
pling E2 concentrations [which occurs frequently in obesity and is
often exceeded (79)] without altering normal INS concentrations
results in about 5% of the INS being bound to E2 at any given
time. Compensating by tripling INS concentrations results in only
2% of the INS being bound to E2, but notably also results in 3% of
the available E2 being tied up in the E2–INS complex. Each com-
pensation, therefore, creates a negative functional effect on one or
both of the hormones.
E2 binds to IR peptides as well as to INS. Tables 2 and 3 esti-
mate the impact of E2 binding to the IR. As Table 2 demonstrates,
E2 binds to INS-like peptides derived from the IR with K d around
780–900 nM, validating the INS-dependent binding of E2 and sug-
gesting possible locations on the IR at which E2 may bind. The
binding constants for E2 binding to IR peptides reported clearly
underestimate the actual binding affinity of E2 for the IR, which
were determined by E2 binding to intact rat IR preparations and
yielded a K d of about 24 nM. There may be several reasons for this
discrepancy. The peptides may not represent the main E2-binding
sites on IR. The peptides may not be in the correct conformation
for binding E2. Binding of E2 to IR may be a cooperative effect
shared by several sites (as is, indeed, binding of INS to the IR). Evi-
dence for cooperativity can be found in the fact that E2 has a much
higher affinity for intact INS than for either the INS A or B chains
by themselves. Finally, the binding measurements were done in
solution, whereas the rat IR was membrane-bound; several studies
have shown that binding of ligands to receptors improves as much
as 100-fold when the receptor molecule is immobilized as the IR
would be in nature (56, 67). Further investigation of the molecular
determinants of E2 binding to the IR and IGFR may be warranted
employing enzyme-linked E2 binding to peptides immobilized on
ELISA plates, or some of the many genetically modified forms of
the IR that have been produced by various laboratories in their
studies of INS binding to the IR. Moreover, since the IR dimerizes
with IGFR, it is possible that E2 will bind the IR:IGFR dimer with
an affinity similar to the IR and IGFR affinities measured here.
E2 clearly inhibits binding of INS to IR in vitro. The impact
of E2 binding to both INS and IR is additive, as Figure 8 demon-
strates, so that the impact of increasing E2 concentrations is greater
than the individual binding percentages shown in Table 3 indi-
cated. Notably, the same effect has been observed in rats in vivo and
in vitro. Hilf et al. (80) report that a 1 mg dose of E2 decreased INS
binding in rats as much as 50% within 24 h while the same effect
was seen in cell culture: “the addition of 10−8 M 17β-estradiol
to the culture medium inhibited cell growth and decreased INS
binding by ~20%.”
While it is clear that estradiol can produce effects on glucose
regulation through a variety of indirect mechanisms, the results
reported here lead us to suggest that direct binding of estradiol
to INS and to the IR may be the main mechanism by which INS
resistance is produced in hyperestrogenemic conditions such as
gestational diabetes, OHSS and PCOS. As Table 4 illustrates, the
concentrations of E2 that produce the severe INS resistance in
GD, OHSS, and PCOS are in the same range as those calculated
to be needed from the binding constants of E2 to INS and the
IR. The fact that cell culture experiments (80), rat experiments
(48–51), clinical observations of human patients undergoing sex-
change therapies also demonstrate E2-concentration-dependent
INS resistance or diabetes (27–29), third-trimester pregnancy (1–
11), OHSS (16, 17), or PCOS (30–39, 47) are in the same concen-
tration ranges as the in vitro effects suggests that the in vitro data
can be extrapolated to in vivo cases.
We emphasize that direct binding of E2 to INS and IR is not
the entire story behind hyperestrogenemia-associated INS resis-
tance. Not all endogenous E2 is free in solution. It is assumed by
the current literature that 80–90% of E2 is reversibly bound to
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Table 3 | Homologies among the amino acid sequences of the peptides used in the present study.
INS B 37-54 E A L Y L V C G E R G F F _ Y T P K T
INSR 91-103 F R V Y G L E S L K D L F
INSR 106-119 L I V I R G S R L F F N Y
INSR 284-300 T Q G K L F F H Y N P K
CONCENSUS L Y _ L _ G _ K _ F F _ Y _ P K
INSR 424-441 N Y S F Y A S D N Q N L R Q L W D W
INSR 233-248 C C H S E C _ L G N C S Q P D D
INS A G I V E Q C C T S I C S L Y Q L E N Y C N
INSR 91-103 F R V Y G L E S L K D L F
CONCENSUS S _ C S L F N _ _ N
INSR 223-234 C K S H G C T A E G L C C
INS A G I V E Q C C T S I C S L Y Q L E N Y C N
INSR 106-119 L I V I R G S R L F F N Y
INSR 233-249 S F C Q D L H H K C K N S R R Q G G
INSR 253-254 T Q G K L F F H Y N P K I
INSR 897-916 H L C V S R K _ H F A L E R G C R L P G
CONCENSUS K L F F _ _ N
INSR 392-404 S G Y L K I R R S Y A L V
INSR 424-441 N Y S F Y A S D N Q N L R Q L W D W
E2 BINDING MOTIF K L F F _ Y _ N
SUBSTITUTIONS 1 R G Y H N K
SUBSTITUTIONS 2 S H P
INS B 37-54 E A L Y L V C G E R G F F Y T P K T
Lys-Pro Insulin E A L Y L V C G E R G F F Y T K P T
Aspart Insulin E A L Y L V C G E R G F F Y T D K T
Glulisine Insulin E A L Y L V C G E R G F F Y T P E T
Glargine Insulin E A L Y L V C G E R G F F Y T P K T R R
Detemir Insulin E A L Y L V C G E R G F F Y T P # T
Degludec Insulin E A L Y L V C G E R G F F Y T P * T
# K-Myristic acid
* E-hexadecanedioic acid
Highly conserved residues are shown in dark shading and semi-conserved residues in light shading. Sequences that bound E2 are shown in normal font; those that
did not bind E2 are shown in italicized font.The motif derived from this study is compared with a portion of the insulin B chain that is modified in many of the modified
commercial insulins that are currently available.
Table 4 | Kinetic effects of estradiol (E2) binding to insulin.
Condition Estradiol
(E2) (M)
Insulin (M) E2–INS
complex (M)
% INS bound
to E2
% E2 bound
to INS
% IR bound
by E2
Normal male, non-pregnant female (1–3) 6×10−11 1.2×10−10 5×10−13 0.2 1.0 0.1
Luteal phase female (1, 2) 6×10−10 1.2×10−10 4×10−12 2.5 1.0 1.2
First trimester pregnancy, OHSS (3–7) 6×10−9 1.2×10−10 3×10−11 25 0.8 12
Third trimester pregnancy (3–5) 4×10−8 1.2×10−10 8×10−11 67 0.2 33
Third trimester pregnancy (3–5) 4×10−8 3.6×10−10 1×10−10 30 0.3 15
Obese type 2 diabetic (3, 54, 64, 65, 68) 2.5×10−10 3.6×10−10 7×10−12 2.1 3.0 1.0
Obese type 2 diabetic (3, 54, 64, 65, 68) 2.5×10−10 1.2×10−10 2.5×10−12 5.0 1.0 2.5
E2 binds to insulin with an affinity of 12 nM and to the insulin receptor (IR) with an affinity of 24 nM. The table illustrates the effects of this binding as a function of
various ranges of estrogen and insulin plasma concentrations. Numbers in brackets refer to references.
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SHBG, so that the effects of E2 on INS and IR may depend on the
E2:SHBG ratio (12, 81). Women who develop gestational diabetes
have 1.5–2.5 times higher E2:SHBG ratios than those who do not.
(81). Further in vitro studies of how E2 is shared between SHBG,
INS, and IR might clarify how this system is regulated. Other ele-
ments of the glucose regulatory and estrogen regulatory systems
mentioned in the Section “Introduction,” such as GLUT and ERα
expression, are certainly involved in the development of INS resis-
tance as well. Additionally, IR activates IR complex 1 (IRC1), which
interacts directly with ERα (61).
In vivo testing of this hypothesis will not be easy, since no
direct techniques currently exist to demonstrate the binding of any
hormone to another hormone or to a receptor in vivo. The demon-
stration of E2–INS and E2–IR complexes from cell cultures, animal
or human plasma, or tissue samples is also fraught with difficul-
ties, since any such experiment will require the use of purification
techniques such as CE, HPLC, etc., to isolate such complexes from
all of the other hormones and proteins in the original samples.
Such purification is unlikely to leave complexes intact. One pos-
sible way to carry out such isolations would be to develop a form
of E2 conjugated to a linker capable of cross-reacting irreversibly
with any peptide or protein to which it binds. Mass spectrometry
could then be used to identify the peptides or proteins to which
the E2 has cross-reacted, and INS and the IR should be among
those identified (in addition to, obviously, estrogen receptors). A
more sensitive approach might be to create an OVEX knock-out
mouse lacking estrogen receptors so that any binding to INS or IR
is more readily identifiable. Development of such OVEX estrogen-
receptor knockouts would also permit another type of experiment;
treat the animal with radioactively labeled estradiol; then look for
evidence of the accumulation of radioactivity in tissues rich in
INS and IRs (e.g., the pancreas). One would expect an overlap at
the microscopic level between some of the radioactivity and flu-
orescent antibodies against IR and INS in tissue slices from such
animals.
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